Home > Insider Trading > Filing (0001179110-22-003107)

Filing Details

Accession Number:: 0001179110-22-003107
Form Type:: 4/A
Zero Holdings:: No
Publication Time:: 2022-05-20 17:00:54
Reporting Period:: 2022-03-01

Accepted Time:: 2022-05-20 17:00:54
Original Submission Date:: 2022-03-02
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1551152	Abbvie Inc.	ABBV	Pharmaceutical Preparations (2834)	320375147

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1659625	O Henry Gosebruch	1 N. Waukegan Road North Chicago IL 60064	Evp, Chief Strategy Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.01 Par Value	Disposition	2022-03-01	15,733	$146.81	62,767	No	4	S	Indirect	In trust
Common Stock, $0.01 Par Value	Disposition	2022-03-01	5,167	$147.60	57,600	No	4	S	Indirect	In trust
Common Stock, $0.01 Par Value	Disposition	2022-03-01	4,000	$148.71	53,600	No	4	S	Indirect	In trust
Common Stock, $0.01 Par Value	Disposition	2022-03-01	100	$149.38	53,500	No	4	S	Indirect	In trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	In trust
No	4	S	Indirect	In trust
No	4	S	Indirect	In trust
No	4	S	Indirect	In trust

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock, $0.01 Par Value	41,623	Direct
Common Stock, $0.01 Par Value	3,457	Indirect	Profit sharing trust

Footnotes

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.31 to $147.30 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.35 to $148.11 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.37 to $148.96 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.38 to $149.39 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reporting person is trustee of a trust established for the benefit of his children. The reporting person disclaims beneficial ownership of all securities held by the trust.
Balance in AbbVie Savings program as of January 31, 2022.
Due to an administrative error, the original Form 4 filed on March 2, 2022 incorrectly reported that the 25,000 securities sold on March 1, 2022 were securities directly owned by the reporting person. Instead, the securities sold on that date were securities indirectly owned in trust by the reporting person. This amended Form 4 corrects that error.